Genetic progression in the pancreatic ducts

American Journal of Pathology

Volumn 156, Issue 6, 2000, Pages 1821-1825

  Hruban, Ralph H ^a   Wilentz, Robb E ^a   Kern, Scott E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

CANCER INFILTRATION; CHEMOPROPHYLAXIS; EARLY DIAGNOSIS; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HETEROZYGOSITY LOSS; HUMAN; ONCOGENE K RAS; ONCOGENE NEU; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; REVIEW;

EID: 0033872039     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65054-7     Document Type: Note

References (39)

1. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colon Cancer Control Study
2. The results of treatment of 4389 cases of preclinical cervical squamous carcinoma
3. Randomised study of screening for colorectal cancer with faecal- occult-blood test
4. Repeated screening for colorectal cancer with fecal occult blood test: A prospective randomized study at Funen, Denmark
5. Cancer statistics, 2000
6. Pancreatic duct hyperplasia and cancer
7. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer
8. Varying grades of epithelial atypia in the pancreatic ducts of humans: Classification based on morphometry and multilvariate analysis and correlated with positive reactions of carcinoembryonic antigen
9. Relation of pancreatic duct hyperplasia to carcinoma
10. Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis
11. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients
12. Progression of pancreatic intraductal neoplasias (high-grade PanIN) to infiltrating adenocarcinoma of the pancreas
13. Pathology of incipient pancreatic cancer
14. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma
15. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium
16. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma
17. Genetic progression and divergence in pancreatic carcinoma
18. Immunohistochemical evaluation of HER-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms
19. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
20. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression
21. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
22. Overexpression of p53 protein in adenocarcinoma of the pancreas
23. The late temporal pattern of BRCA2 inactivation in pancreatic intraductal neoplasia: Evidence and implications
24. K-ras oncogene activation in adenocarcinoma of the human pancreas: A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
25. Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: A newly described and characterized entity
26. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia
27. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation
28. Gatekeepers and caretakers
29. The c-erbB-2 proto-oncogene in human pancreatic cancer
30. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas
31. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
32. Tumor-suppressive pathways in pancreatic carcinoma
33. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
34. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
35. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic: A new marker of DPC4 inactivation
36. Progression model for pancreatic cancer
37. Recent advances in chemoprevention of cancer
38. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
39. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis